Table 1

Demographic and clinical characteristics

VariableAβ-negative non-demented (n = 117)Aβ-positive non-demented (n = 94)
Age (years)68.8 ± 6.271.4 ± 6.3
Female (%)71 (60%)49 (52%)
Education (years)16.3 ± 2.516.4 ± 2.6
APOE ε4 carriers (%)30 (26%)55 (67%)
MMSE28.5 ± 1.228.4 ± 1.6
Tau-PET follow-up time (years)3.3 ± 1.62.6 ± 1.2
MCI (%)74 (63%)74 (79%)
VariableAβ-negative non-demented (n = 117)Aβ-positive non-demented (n = 94)
Age (years)68.8 ± 6.271.4 ± 6.3
Female (%)71 (60%)49 (52%)
Education (years)16.3 ± 2.516.4 ± 2.6
APOE ε4 carriers (%)30 (26%)55 (67%)
MMSE28.5 ± 1.228.4 ± 1.6
Tau-PET follow-up time (years)3.3 ± 1.62.6 ± 1.2
MCI (%)74 (63%)74 (79%)

Data are presented as mean ± SD unless specified otherwise. APOE ε4, apolipoprotein E genotype (carrying at least one ε4 allele); MMSE, Mini-Mental State Evaluation; MCI, mild cognitive impairment.

Table 1

Demographic and clinical characteristics

VariableAβ-negative non-demented (n = 117)Aβ-positive non-demented (n = 94)
Age (years)68.8 ± 6.271.4 ± 6.3
Female (%)71 (60%)49 (52%)
Education (years)16.3 ± 2.516.4 ± 2.6
APOE ε4 carriers (%)30 (26%)55 (67%)
MMSE28.5 ± 1.228.4 ± 1.6
Tau-PET follow-up time (years)3.3 ± 1.62.6 ± 1.2
MCI (%)74 (63%)74 (79%)
VariableAβ-negative non-demented (n = 117)Aβ-positive non-demented (n = 94)
Age (years)68.8 ± 6.271.4 ± 6.3
Female (%)71 (60%)49 (52%)
Education (years)16.3 ± 2.516.4 ± 2.6
APOE ε4 carriers (%)30 (26%)55 (67%)
MMSE28.5 ± 1.228.4 ± 1.6
Tau-PET follow-up time (years)3.3 ± 1.62.6 ± 1.2
MCI (%)74 (63%)74 (79%)

Data are presented as mean ± SD unless specified otherwise. APOE ε4, apolipoprotein E genotype (carrying at least one ε4 allele); MMSE, Mini-Mental State Evaluation; MCI, mild cognitive impairment.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close